ASDM licences synthetic bone substitute with University of Sydney

THE ROADHOUSE PHARMACY: Orthopaedic devices manufacturer, Advanced Surgical Design and Manufacture Limited (ASDM) (ASX: AMT) has executed a global Licence Agreement with The University of Sydney relating to a composite biocompatible ceramic material known as Sr-HT-Gahnite.

ASDM is to facilitate the commercialisation of veterinary and orthopaedic solutions based on the composite biocompatible ceramic material developed by the University.

“Existing synthetic bone substitute materials are unable to be used to treat bone loss in load bearing applications,” ASDM CEO Tom Milicevic said in the company’s announcement to the Australian Securities Exchange.

“Consequently, bone autograft and allografts and/or metal implants are required.

“In preliminary studies, Sr-HT-Gahnite has duplicated the mechanical strength, elasticity and bioactivity of bone.

“Importantly, it is 100 times mechanically stronger than synthetic bone substitute materials in clinical use.”

Milicevic described the project as an exciting one for ASDM in that it fits the company’s strategy of developing a portfolio of products in orthopaedics.
 
“This material is a novel breakthrough technology with huge global potential,” he continued.

“According to the 2010 GlobalData report, the Bone Graft market was valued at US$1.9 billion and is forecast to grow by a CAGR of 8.3 per cent more than doubling the market by 2020.”
 
The University of Sydney said it was pleased to be working closely with ASDM.

“We are very excited by the opportunity to work so closely with a leading Australian orthopaedic device manufacturer,” University of Sydney commercial development and industry partnerships director Andrew Tindell said.

“This materials technology represents the culmination of 22 years of world leading research and it is always rewarding when the University sees the outputs of its work taken up by industry, developing products and bringing them to the market.”

Website: www.asdm.com.au